Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released Feb 26, 2020, before the open
10-K filed Feb 26, 2020, 57 days after period end · 0001193125-20-049021
| Metric | Q4 2019 | Q4 2018 | Q4 2017 | Q4 2016dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$27.74M | -$11.48M | -$8.45M | -$7.75M |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| EPS Diluted | -$1.80 | -$0.75 | -$0.67 | — |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.